Chemotherapy and Cutaneous Toxicities: Implications for Oncology Nurses

Seminars in Oncology Nursing

Volumn 22, Issue 3, 2006, Pages 144-151

  Viale, Pamela Hallquist ^a  

^a Camino Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ALOPECIA; ARTICLE; CHEMICALLY INDUCED DISORDER; CONTRAST MEDIUM EXTRAVASATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; EARLY DIAGNOSIS; GRAFT VERSUS HOST REACTION; HOSPITALIZATION; HUMAN; HYPERPIGMENTATION; NAIL DISEASE; NEOPLASM; NURSE ATTITUDE; NURSING; NURSING ASSESSMENT; ONCOLOGY NURSING; ORGANIZATION AND MANAGEMENT; PATIENT EDUCATION; SKIN CARE; SKIN DISEASE;

ALOPECIA; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; EARLY DIAGNOSIS; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; GRAFT VS HOST DISEASE; HUMANS; HYPERPIGMENTATION; NAIL DISEASES; NEOPLASMS; NURSE'S ROLE; NURSING ASSESSMENT; ONCOLOGIC NURSING; PATIENT EDUCATION; SEVERITY OF ILLNESS INDEX; SKIN CARE; SKIN DISEASES;

EID: 33746684944     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2006.04.007     Document Type: Article

References (26)

1. Alley E., Green R., and Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol 14 (2002) 212-216
2. Leo S., Taveri R., Campanella G.A., et al. Dermatological toxicity from chemotherapy containing 5-fluorouracil. J Chemother 6 (1994) 423-426
3. Guillot B., Bessis D., and Dereure O. Mucocutaneous side effects of antineoplastic chemotherapy. Expert Opin Drug Safety 3 (2004) 579-587
4. Fawcett R.S., Linford S., and Stulberg D.L. Nail abnormalities. Clues to systemic disease. Am Fam Physician 69 (2004) 1417-1424
5. Minisini A.M., Tosit A., Sobrero A.F., et al. Taxane-induced nail changes. Incidence, clinical presentation and outcome. Ann Oncol 14 (2003) 333-337
6. Marrs J., and Newton S. Chemotherapy-induced nail changes. An unsightly nuisance. Clin J Oncol Nurs 8 (2004) 527-528
7. Monti M., Mancini L.L., Ferrari B., et al. Case 2. Cutaneous toxicity induced by cetuximab. J Clin Oncol 21 (2003) 4651-4652
8. Robert C., Soria J., Spatz A., et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6 (2005) 491-500
9. Hussain S., Anderson D., Salvatti M.E., et al. Onycholysis as a complication of systemic chemotherapy. Cancer 88 (2000) 2367-2371
10. Scotte F., Tourani J., Banu E., et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 23 (2005) 4424-4429
11. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0. Rockville, MD, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Department of Health and Human Services. June 10, 2003.
12. Agterof M.J., and Biesma D.H. Bortezomib-induced skin lesions. N Engl J Med 352 (2005) 2534
13. Polovich M., White J.M., and Kelleher L.O. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. Ed 2 (2005), Oncology Nursing Society, Pittsburgh, PA
14. Cohen A.D., Mermershtain W., Geffen D.B., et al. Cutaneous photosensitivity induced by paclitaxel and trastuzumab therapy associated with aberrations in the biosynthesis of porphyrins. J Derm Treat 16 (2005) 19-21
15. Wilkes J.M., and Doyle D. Palmar-plantar erythrodysesthesia. Clin J Oncol Nurs 9 (2005) 103-106
16. Lin E.H., Morris J., Chau N.K., et al. Celecoxib attenuated capecitabine induced hand and foot syndrome (HFS) and diarrhea and improved time to tumor progression in metastatic colorectal cancer. Proc Am Soc Clin Oncol 21 (2002) 138b [abstr 2364]
17. Eich D., Scharffetter-Kochanek K., Eich H., et al. Acral erythrodysesthesia caused by intravenous infusion of docetaxel in breast cancer. Am J Clin Oncol 25 (2002) 599-602
18. Demircay Z., Gurbuz O., Alpdog R.B., et al. Chemotherapy-induced acral erythema in leukemic patients. A report of 15 cases. Int J Dermatol 36 (1997) 593-598
19. Millot F., Auriol F., Brecheteau P., et al. Acral erythema in children receiving high-dose methotrexate. Pediatr Dermatol 16 (1999) 398-400
20. Gobel B.H. Chemotherapy-induced hypersensitivity reactions. Oncol Nurs Forum 32 (2005) 1027-1035
21. Gonzalez I.D., Saez R.S., Rodilla R.S., et al. Hypersensitivity reactions to chemotherapy drugs. Alergol Immunol Clin 15 (2000) 161-181
22. Apisarnthanarax N., and Duvic M. Dermatologic complications of cancer chemotherapy. In: Bast R.C., Kufe D.W., RE P., et al. (Eds). Cancer Medicine. Ed 5 (2000), Decker, Hamilton, Ontario. http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=cmed.chapter.38915 Available at: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=cmed.chapter.38915. (accessed June 8, 2006).
23. Schulmeister L., and Camp-Sorrell D. Chemotherapy extravasation from implanted ports. Oncol Nurs Forum 27 (2000) 531-538
24. Mandanas RA. Graft versus host disease: E Medicine. Available at: http://www.emedicine.com/med/topic926.htm. (accessed June 8, 2006).
25. O'Rourke M.E., and High K. Diagnosing graft versus host disease. Clin J Oncol Nurs 4 (2000) 47-48
26. Perez-Soler R., Delord J.P., Halpern A., et al. HER1/EGFR inhibitor-associated rash. Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10 (2005) 345-356